Weight-loss jabs could 'significantly lower' risk of dementia Wednesday, June 25, 2025 semaglutide dementia ozempic wegovy diabetes alzheimers glp1 weightloss cardiovascular t2diabetes A groundbreaking study has found that semaglutide, the active ingredient in the diabetes drug Ozempic and the weight-loss injection Wegovy, may significantly reduce the risk of dementia in people with type 2 diabetes. … Read More